United Therapeutics Corp key statistics and ratios

In fiscal 2025, United Therapeutics Corp had return on equity of 19.7%, an operating margin of 46.9% and a current ratio of 6.60. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

United Therapeutics Corp: financial ratios, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Gross margin	88.3%	88.4%	87.8%	85.9%	87.4%	89.5%	—	95.5%	93.9%	87.8%	91.9%	92.7%	92.7%	92.2%	88.9%	89.2%	87.9%	86.1%
Operating margin	7.2%	28.9%	42.8%	46.0%	26.2%	41.8%	47.7%	66.4%	47.2%	49.5%	−12.9%	40.0%	33.0%	50.6%	50.9%	47.9%	46.9%	44.4%
Net margin	5.4%	17.9%	29.3%	33.2%	15.6%	26.4%	44.5%	44.6%	24.2%	36.2%	−7.2%	34.7%	28.2%	37.6%	42.3%	41.5%	41.9%	41.6%
Free-cash-flow margin	1.2%	32.5%	28.8%	23.1%	35.2%	23.9%	22.7%	37.9%	22.5%	36.5%	−20.0%	46.9%	28.3%	34.3%	32.1%	37.6%	32.7%	34.6%
Return on equity	3.0%	13.8%	23.8%	30.0%	14.9%	27.2%	46.0%	41.5%	21.1%	24.1%	−3.8%	16.7%	12.9%	16.6%	18.3%	19.2%	19.7%	19.4%
Return on assets	1.9%	8.5%	14.8%	19.4%	9.4%	17.1%	32.0%	31.6%	16.1%	18.8%	−2.9%	12.1%	9.7%	13.0%	14.9%	16.4%	17.5%	17.4%
Asset turnover	0.34	0.48	0.50	0.58	0.60	0.65	0.72	0.71	0.66	0.52	0.40	0.35	0.34	0.35	0.35	0.40	0.42	0.42
Current ratio	0.98	1.78	2.65	3.78	1.33	1.90	2.89	4.29	3.26	6.39	4.03	6.70	7.61	9.85	4.41	5.25	6.60	5.73
Debt to equity	33.7%	34.5%	20.5%	19.0%	22.7%	—	0.3%	0.0%	23.8%	17.9%	30.6%	23.6%	20.2%	16.7%	11.7%	4.7%	—	0.0%
Interest cover (operating income ÷ interest)	2.0x	8.7x	14.9x	25.3x	16.2x	30.6x	148.7x	—	90.5x	57.9x	n/m	25.3x	29.9x	30.2x	20.0x	32.1x	76.5x	116.8x
Effective tax rate	−3.7%	28.3%	27.4%	30.9%	37.4%	35.2%	37.6%	32.7%	45.7%	22.4%	—	19.4%	19.9%	23.5%	22.7%	22.3%	22.1%	16.7%
R&D as % of revenue	33.5%	27.9%	24.2%	18.9%	26.8%	18.8%	16.7%	9.2%	15.3%	22.0%	81.6%	24.1%	32.0%	16.7%	17.5%	16.7%	17.3%	17.5%
SG&A as % of revenue	47.9%	31.8%	21.1%	22.0%	35.3%	29.6%	30.9%	19.8%	19.1%	16.3%	—	—	27.7%	24.9%	20.5%	24.7%	23.7%	24.2%
Capital spending as % of revenue	26.6%	3.1%	4.8%	12.2%	2.9%	3.7%	3.4%	2.4%	5.0%	11.3%	5.8%	4.0%	7.2%	7.2%	9.9%	8.6%	16.4%	18.8%
Free cash flow ÷ net income	22.2%	182.1%	98.3%	69.5%	225.3%	90.5%	51.1%	84.9%	92.8%	100.8%	—	135.3%	100.3%	91.3%	75.9%	90.4%	78.0%	83.4%
Dividends and buybacks ÷ free cash flow	—	—	99.0%	88.8%	10.8%	156.9%	118.5%	82.6%	64.4%	—	—	—	—	0.0%	0.0%	92.5%	96.1%	228.7%

US$ thousands unless shown otherwise. Fiscal quarters.

United Therapeutics Corp: financial ratios, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Gross margin	88.9%	89.7%	88.4%	89.0%	87.4%	86.9%	82.9%	87.3%
Operating margin	45.8%	48.6%	48.2%	45.6%	48.6%	45.1%	41.7%	42.2%
Net margin	41.3%	40.9%	40.6%	38.8%	42.4%	46.1%	35.2%	42.5%
Free-cash-flow margin	40.2%	34.6%	48.6%	16.2%	44.0%	21.9%	46.4%	26.2%
Current ratio	4.58	5.25	5.46	7.26	6.40	6.60	4.79	5.73
R&D as % of revenue	13.8%	18.2%	18.8%	16.8%	15.9%	17.7%	17.7%	18.7%
SG&A as % of revenue	29.3%	22.9%	21.4%	26.6%	22.8%	24.1%	23.6%	26.4%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

3 of 3 checks passed · June 30, 2026

What it owns · $7.2bn

Short-term assets $3.5bnLonger-term assets $3.7bn

What it owes, and who funded it · $7.2bn

Short-term liabilities $608mLonger-term liabilities $212mShareholders' equity $6.4bn

Short-term assets cover short-term liabilities $3.5bn of assets due within a year against $608m of liabilities due within a year.
Short-term assets cover long-term liabilities $3.5bn short-term assets against $212m of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Operating income of $1.4bn against $12m of interest.

From United Therapeutics Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

75 /100

Strong moat

How hard United Therapeutics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 20 / 20

Cash operating profit has been a median 28.0% of total assets over 10 years.
Pricing power 19 / 20

Gross margin has been a median 91.0%, moving by 3.4 percentage points (standard deviation) across 10 years.
Durability 10 / 20

Operating margin has been a median 47.0%; its worst year was -10.0%.
Cash conversion 19 / 20

Free cash flow was positive in 9 of 10 years, at a median 34.7% of revenue.
Discipline 13 / 20

The diluted share count rose 2.2% over five years; stock-based pay has been a median 4.7% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (80 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: BNTX vs UTHR BMRN vs UTHR NTRA vs UTHR EXEL vs UTHR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from United Therapeutics Corp's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to United Therapeutics Corp.